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especially coronary artery disease. The incidence of myocardial 
infarction is 30%-60% higher [1], and its onset in RA is approximately 
10 years earlier [2,3]. The age- and sex-adjusted mortality rate for 
cardiovascular disease (CVD) in RA patients is 50%-100% higher 
than the rate in the general population [4]. Increased prevalence 
of diabetes, hypertension, hypercholesterolemia, and metabolic 
syndrome in RA could explain the increased mortality; however, RA 
alone is also responsible for the excess of cardiovascular morbidity 
and mortality [5]. The traditional atherosclerotic risk factors alone 
cannot explain the accelerated atherosclerosis in RA patients. Some 
studies have reported that chronic inflammation might play a major 
role in accelerated atherosclerosis [6]. Inflammation can cause 
abnormal lipid metabolism and also transform fatty streaks into 
unstable plaques. Additionally, there is evidence that atherosclerosis 
is an inflammatory disease [7].
The increased prevalence of coronary artery disease and the high 
CVD mortality rate results from chronic systemic inflammation 
and enhanced instability of atherosclerotic plaques. These factors, 
in addition to traditional CVD risk factors, are thought to impact 
RA [8]. RA patients treated with disease-modifying anti-rheumatic 
drugs (DMARDs) showed a reduced risk for CVD compared to those 
without DMARDs [9]. In a case control study, Suissa, et al. reported 
that RA patients treated with DMARDs displayed a decreased 
prevalence of acute myocardial infarction [10].
We used methotrexate to examine the role of immunomodulation 
on the activation of different molecular inflammatory cytokines that 
could generate a microenvironment that supports cardiovascular 
remodelling.
Methods
Animals and experimental design
All procedures were performed according to institutional 
guidelines for animal experimentation. The protocol was submitted 
and approved by the Institutional Committee for Laboratory Animal 
Use and Care (ICLAUC) at the School of Medicine-UNCuyo. Thirty-
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Introduction
Increasing evidence suggests that immune activation and 
inflammatory mediators may play a role in the development and 
progression of atherosclerosis. Several studies have shown that 
patients with some diseases characterized by inflammatory mediator 
activation, which rheumatoid arthritis (RA), presented accelerate 
atherosclerosis. RA is a systemic inflammatory disease and the 
most common cause of death is due to accelerated atherosclerosis, 
Abstract
Background: In this study, we used Methotrexate (Mtx) to 
examine the role of immunomodulation on the activation of IL-6 and 
VCAM-1, which could generate a microenvironment that supports 
cardiovascular remodelling.
Methods: Male WKY and SHR rats were separated into five 
groups: Control, FFR: WKY rats receiving a 10% (w/v) fructose 
solution during all 12 weeks, SHR, FFHR: SHR receiving a 10% 
(w/v) fructose solution during all 12 weeks and FFHR+Mtx (0,3 mg/
kg intraperitoneal one injection per day week for 6 weeks) (n = 8 
per group). Metabolic variables and systolic blood pressure were 
measured. Cardiac and vascular remodelling was also evaluated. 
To assess this, IL-6R and VCAM-1 immunostaining techniques 
were used.
Results: The FFHR experimental model developed metabolic 
syndrome, vascular and cardiac remodelling, and vascular 
inflammation because of increased expression of IL-6 and VCAM-1. 
Chronic treatment with Mtx completely or partiality reversed the 
variables studied.
Conclusions: The results demonstrated an impact on 
immunomodulation after mtx treatment, which included a reduction 
in vascular inflammation and a favourable reduction in metabolic 
and structural parameters.
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day-old male Wistar Kyoto (WKY) and spontaneously hypertensive 
rats (SHR) were fed a standard commercial chow diet ad libitum. All 
rats were housed in a room under controlled temperature (20ºC) and 
humidity conditions with a 12-hour light/dark cycle during the 12-
week experimental period. Metotrexate (MtxMetotrexate Mtx) was 
administered to the following groups during the last six weeks of the 
study.
I-Control (W): WKY rats receiving food and drinking water 
(DW) ad libitum;
II-SHR receiving food and DW ad libitum;
III-Fructose-fed rats (FFR): WKY rats receiving a 10% (w/v) 
fructose (Parafarm, Buenos Aires, Argentina) solution in the DW 
during all 12 weeks,
IV-Fructose-fed hypertensive rats (FFHR): SHR rats receiving a 
10% (w/v) fructose solution in the DW during all 12 weeks;
V- FFHR+Mx: FFHR receiving 0.3 mg/kg of Mxtby intraperitoneal 
(i.p.) administration once a week for 4 weeks.
MTX is a folic acid antagonist on the basis of its competitive 
binding to dihydrofolate reductase, an enzyme involved in de novo 
synthetic pathways for purine and pyrimidine precursors of DNA 
and RNA required for cell proliferation. Therefore, Mtx has been used 
extensively for treatment of neoplastic diseases in doses of 20 to 250 
mg/kg. Low doses of Mtx were used (0.1-0.3 mg/dL once week for 4-6 
weeks) because it has been reported anti-atherosclerotic effects via its 
anti-inflammatory actions.
At the end of the experimental period, the rats were euthanized 
with sodium pentobarbital (50 mg/Kg i.p.), blood samples were 
taken, and the arteries and organs were aseptically excised for 
measurements. At this dose, no gastrointestinal damage has been 
described. In the same way, the macroscopic revision of the gastric 
tissue was performed in random animals, and no lesions were found 
at this level.
Systolic blood pressure measurement
The systolic blood pressure (SBP) was monitored indirectly in 
conscious, pre-warmed rats that were mildly restrained by the tail-
cuff method and recorded on a Grass Model 7 polygraph (Grass 
Instruments Co., Quincy, MA, USA). The rats were habituated to the 
apparatus several times before measurement.
Biochemical determinations
HOMA index and intra-peritoneal glucose tolerance test.
The fasting plasma insulin was assayed using the ACS: 180SE 
automated chemiluminescence system (Bayer, Germany). The plasma 
glucose levels were assayed using a commercial colorimetric method 
(Wiener Lab., Argentina). The HOMA was used as an index to measure 
the degree of insulin resistance. HOMA was calculated using the 
following formula: [insulin (µU/mL) × glucose (mmol/L) /22.5] [11].
Three days before the end of the experimental period, a glucose 
tolerance test (GTT) was performed. Rats were fasted overnight and 
were slightly anesthetized with pentobarbital. Then, glucose was 
administered (2 g/kg i.p.). Blood samples were taken by tail bleeding 
at 0, 30, 60, and 90 minutes after injection to determine the plasma 
glucose concentration. The total area under the curve was calculated 
as mmol/L/90 min.
Assessment of the lipid profile
At the end of the experimental period, blood samples were 
drawn from the animals after fasting for 12 hours. The total plasma 
cholesterol, HDL cholesterol, and triglycerides were assessed using 
photocolourimetric enzymatic methods (Wiener Lab., Rosario, 
Argentina). The data are expressed in mmol/L.
Oxidative stress determinations
Measurement of plasma thiobarbituric acid-reactive substances 
(TBARS).
To demonstrate the effect of increased oxidative stress at the 
vascular level, plasma lipid peroxidation was assessed by determining 
the TBARS concentration. This assay is based on the reaction 
between plasma malondialdehyde, a product of lipid peroxidation, 
and thiobarbituric acid, as previously described [8]. No correction 
for sample protein content was necessary because of the nature of 
sample [9].
Measurement of vascular nad(p)h-oxidase activity
The lucigenin-derived chemiluminescence assay was used to 
determine the NAD(P)H-oxidase activity in a segment of the thoracic 
aorta, as previously described [8]. To assess NAD(P)H-oxidase 
activity, NADPH  (500 µmol/L) was added, and chemiluminescence 
was immediately measured in a liquid scintillation counter (LKB 
Wallac Model 1219 Rack-Beta Scintillation Counter, Finland) set 
in the out-of-coincidence mode. Time-adjusted and normalized-to-
tissue-weight scintillation counters were used for the calculations. 
The measurements were repeated in the absence and presence of 
diphenylene iodinium (DPI) (10-6 mol/L), which inhibits flavin-
containing enzymes, including NAD(P)H oxidase [10,12].
Relative heart weight
To evaluate cardiac hypertrophy, we measured the relative 
heart weight (RHW). Briefly, the heart was separated from the great 
vessels, placed ina phosphate-buffered saline (PBS) solution, blotted 
with tissue paper to remove the blood, and weighed. The total heart 
weight was corrected according to the ratio between the heart weight 
(milligrams) and 100 grams of the total body weight before sacrifice.
Tissue preservation
Tissue samples for histopathology were processed as previously 
reported [10]. Samples from all rats were used for these observations. 
Anesthetized animals were briefly perfused with PBS (298 mOsmol/
KgH2O, pH 7.40, 4 °C) to remove the blood. The mesenteric arteries 
were perfused in vivo with the same solution through the mesenteric 
artery for 5 min. For the histological studies, the arteries were also 
perfused with a 4% paraformaldehyde solution for 10 min and fixed 
in paraffin wax. Five-micron-thick tissue slices were transversely cut 
across the mesenteric tissue on a microtome (Microm HM, Germany) 
and processed for histological studies. A similar procedure was 
applied for heart tissue preservation by aortic retrograde perfusion.
Quantitative histomorphometry to determine cardiac 
hypertrophy
Histomorphological analyses were conducted on slices from the 
outer (free) wall of the left ventricle (LV) of the heart. Estimations 
of the cardiomyocyte area were made from sections stained with 
Masson trichrome solution. Areas with transverse sections of 
myofibres were selected. The contour of the fibres was then drawn 
manually. The total cardiomyocytearea was expressed in square 
micrometres (μm2).
Arterial structure
The medial layers of the mesenteric arteries were measured to 
assess changes in the structure of the arterial walls. The slices were 
dyed and examined as previously described [10]. Non-transverse 
sectioned arteries were excluded from the investigation. Next, the 
lumen-to-media ratio (i.e., the ratio of the internal diameter to the 
medial (L/M) thickness) was calculated. Fifty slices from each animal 
were processed and analysed to obtain an average value for each rat. 
The average values were then used for the final analysis.
Immunohistochemistry (IHC) and digital confocal microscopy
A rabbit antibody against the C-terminus of rat NF-kB p65 
subunit [Rel A] was obtained from Millipore International Inc. 
(AB1604b; Amsterdam, Netherlands), and a goat anti-rat VCAM-
1 (C-19) antibody was obtained from Santa Cruz Biotechnology 
Inc. (sc-1504; Santa Cruz USA). Tissue sections were cut at a 3-μm 
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thickness from paraffin-embedded blocks. The antibodies were 
diluted to 1:1000. The primary incubations were carried out for 1 
hour at 21-22 °C, followed by six 5-min washes using PBS with Triton 
X-100. The secondary antibodies, anti-rabbit IgG TR and anti-goat 
IgG FITC (Sigma-Aldrich), were diluted in PBS alone according to 
the manufacturer’s instructions.
The images were captured with Nikon EZ-C1 3.00 software on a 
Nikon Diaphot TMD microscope.
SDS-PAGE and immunoblot analysis
The mesenteric tissue from each rat was washed in PBS, and 
the proteins were extracted in a cold extraction buffer (20 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X-100) 
and a protease inhibitor mixture (P2714, Sigma). The samples 
were sonicated for 15 s (three times with 10-s intervals),with a 
30-min extraction for 30 min at 4 °C. The sample extracts were 
clarified by centrifugation at 14,000 × g for 20 min and used 
immediately or stored at -20 °C. The proteins were separated on 
10% polyacrylamide gels and transferred to 0.22-µm nitrocellulose 
membranes (GE, Germany). Nonspecific reactivity was blocked by 
incubation for 1 h at room temperature in 5% non-fat dry milk 
dissolved in washing buffer (PBS, pH 7.6, 0.2% Tween 20). The 
blots were incubated with anti-p65, anti-VCAM-1 antibodies (0.2 
µg/mLin blocking solution) and anti-IL6R alpha (sc-660) rabbit 
IgG for 60 min at room temperature. Horseradish peroxidase-
conjugated goat anti-rabbit-IgG and swine anti-goat-IgG were 
dissolved in blocking buffer and used as secondary antibodies (0.25 
µg/mL, blots were incubated for 45 min at room temperature). 
Excess first and second antibodies were removed by washing 
five times for 5 min each time in blocking solution. Detection 
was accomplished with an enhanced chemiluminescence system 
(ABC, Dako System) and subsequent exposure to Kodak X-AR 
film (Eastman Kodak) for 5-30 s.
Measurement of the concentration of high-sensitive C 
Reactive Protein (hs-CRP)
The plasma hs-CRP concentrations were measured using a 
turbidimetric assay (Bayer Advia 1650, AG Leverkiusen). The data 
are expressed in mg/L.
Reagents
Unless otherwise noted, all reagents were purchased from Sigma 
Chemical Co, MO, USA.
Statistical and data analysis
The data are expressed as the mean ± SEM. The statistical 
significance of the comparisons between all groups was assessed by 
one-way ANOVA followed by a Bonferroni post-test. A two-sided 
p-value of less than 0.05 was considered significant.
Results
Methotrexate improves metabolic indexes and blood pressure
Chronic administration of fructose induced several alterations 
that are considered in the cluster of risk factors that characterize 
MS. The comparison between the HOMA index and the areas under 
the GTT curve indicated that the FFR and FFHR developed glucose 
intolerance, as demonstrated by the significantly increased HOMA 
index and area values compared to the control rats (Table 1).
Furthermore, the animals in the FFR and FFHR groups also 
displayed significant differences in the levels of triglycerides and 
HDL-cholesterol when compared to the controls (Table 1). The SHR, 
FFR, and FFHR also displayed significant differences in the levels of 
hs-CRP when compared to the WKY rats. The FFHR group displayed 
higher hs-CRP levels than the other groups. Mtx reduced all of these 
variables to the levels observed in WKY rats (Table 1).
Table 1 also shows the time-course of the changes in SBP during 
the experimental period. By the sixth week, the SBP values of the 
FFHR and SHR groups were significantly increased compared to 
the control group, and there was an increase in pressure in the FFR 
group, which was lower but still significant. Treatment with Mtx 
did not return the SBP values to those of the control animals. These 
results on the value of blood pressure are statistically significant but 
not clinically significant because the reduction of this value was not 
less than 140 mmHg.
Methotrexate results in the recovery of the oxidative status
Table 2 indicates that NAD(P)H-oxidase activity and the plasma 
TBARS concentration was significantly higher in the aortas of FFHR 
when compared to those from the other groups. In previous studies 
the arterial eNOS activity in the FFHR group was significantly 
reduced, contributing to a decrease in the production and consequent 
bioavailability of nitric oxide (NO) [10,13-15].
Administration of Mtx effectively reduced superoxide production 
by reducing the activity of NAD(P)H oxidase and TBARS (Table 2), 
which normalized the endothelial oxidative status (Table 2).
Table 1: Metabolic and cardiovascular variables.
Variable WKY FFR SHR FFHR FFHR+Mtx
Fasting glucose (mmol/L) 4.88 ± 0.1 6.44 ± 0.2* 5.0 ± 0.2 6.5 ± 0.2*^ 5.0 ± 0.1**
Fasting triglycerides (mmol/L) 0.8 ± 0.0 1.9 ± 0.0*# 1.0 ± 0.0 1.9 ± 0.1*# 0.9 ± 0.2**
HOMA  (µU/mL insulin x mmol/L glucose) / 22.5 4.00 ± 0.2 11.0 ± 0.1*# 7.1 ± 0.15* 15.1 ± 0.5*#^ 4.50 ± 0.5**
Area under glucose tolerance test curve (mmol / L / 90 min) 881 ± 64 1352 ± 21*# 1300 ± 35* 1909 ± 51*#^ 1005 ± 67**
HDL cholesterol (mg/dl) 21.5 ± 0.3 13.2 ± 0.4*# 19 ± 1.0* 11.6 ± 1.5*#^ 18.2 ± 1.3**
High-sensitivity C reactive Protein (mg/dL) 1.5 ± 0.1 3.5 ± 0.0 3.1 ± 0.1 4.5 ± 0.1*#^ 0.9 ± 0.3**
Systolic blood pressure (mmHg)
Baseline 105 ± 3 102 ± 1.0 103 ± 1 105 ± 3 105 ± 2
6 weeks 110 ± 1.0 129 ± 2.0* 165 ± 2* 172 ± 3*# 170 ± 3*
12 weeks 115 ± 1.3 139 ± 3.0* 178 ± 1*# 185 ± 2*#^ 135 ± 1.7**
The above values correspond to metabolic and cardiovascular variables. Symbols indicate: *p < 0.001 vs. WKY; ^p < 0.001 vs. SHR; #p < 0.01 vs. FFR. ** vs. FFHR.
Table 2: Oxidative stress and morphometric variables.
Variable WKY FFR SHR FFHR FFHR+Mtx
NAD(P)H oxidase activity (counts/min/mg tissue) 40.5 ± 6 133 ± 5* 160 ± 9.1*# 297 ± 9.1*#^ 41 ± 5.1*^**
TBARS (µmol/L) 1 ± 0.1 2.2 ± 0.1* 1.69 ± 0.1* 2.8 ± 0.1*#^ 1.0 ± 0.7#^**
Relative heart weight (mg/100 g body weight) 225 ± 4 290 ± 4* 330 ± 1.8*# 400 ± 4*#^ 290 ± 4**
Myocardiocyte area (µm2) 1682 ± 69 2066 ± 57* 2222 ± 78*# 3242 ± 55*#^ 1688 ± 34**
Lumen/media relationship in mesenteric arteries 13.9 ± 0.3 10.2 ± 0.5* 8.9 ± 0.6*# 8.45 ± 0.2*# 14.8 ± 2**
The above values correspond to oxidative stress and morphometric variables. Symbols indicate: *p < 0.001 vs. WKY; ^p < 0.001 vs. SHR; #p < 0.01 vs. FFR. ** vs. FFHR.
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Methotrexate modifies cardiac and vascular hypertrophy
The RHW and myocardiocyte area was significantly higher in the 
FFR, SHR, and FFHR groups than in the control rats, demonstrating 
myocardial hypertrophy in these experimental models (Table 2). 
The FFHR group always displayed a significantly reduced L/M 
when compared to the corresponding arteries from the WKY group. 
This result was also observed in the FFR and SHR groups. Chronic 
treatment with Mtx significantly reduced myocardial hypertrophy 
and vascular remodelling in the FFHR model (Table 2).
Methotrexate impacts vascular inflammation
The expression of NF-kB, VCAM-1, and IL-6R, products that 
actively participate in vascular inflammation, is shown in figure 1. Both 
molecules were detected by IHC. The expression of these molecules 
in the FFHR group increased significantly compared to the control 
group (W). The right panel shows a representative image of a WB 
for these proteins. The average optical density significantly increased 
in mesenteric artery homogenates from the FFHR and FFR groups 
compared to the controls. The distribution of the control protein load 
was similar for all groups. This work is the first to show an increase 
in the IL-6 alpha receptor in the vascular wall. This observation could 
explain vascular changes as well as the interaction with the renin-
angiotensin system through different intracellular cascades.
Mtx reduced the activation and nuclear translocation of NF-κB 
(p65 fraction), VCAM-1and IL-6 alpha receptor expression. This 
observation could be explained because in the FFHR group, nuclear 
factor NF-κB production was more important due to the production 
of superoxides as a result of the insulin-resistance status. This may 
also be a determining factor in the reduction of vascular remodelling, 
as previously shown.
Discussion
In this article, we demonstrated that MTX reduces vascular 
inflammation that is accompanied by a reduction in metabolic and 
structural parameters.
In papers, as first noted in the Cholesterol and Recurrent Events 
(CARE) trial more than a decade ago, the benefits of pravastatin were 
particularly pronounced among patients with evidence of ongoing 
vascular inflammation. The AFCAPS/TexCAPS trial and JUPITER 
trial, tested the hypothesis that markers of inflammation can identify 
a group of patients who do not qualify for statin therapy because of 
normal lipid levels but who might nonetheless benefit from treatment. 
Further analyses indicated that the reduction in cardiovascular events 
derived from both the observed reduction in vascular inflammation, 
as measured by hsCRP, and from reductions in LDL-C.
The Cardiovascular Inflammation Reduction Trial’s primary aim 
tests this hypothesis, a matter of considerable clinical therapeutic 
as well as mechanistic biological interest (CIRT, ClinicaTrials.
gov NCT01594333). Before CARE results, novel approaches to 
preventing the macrovascular complications of insulin resistance 
and diabetes are urgently needed. Patients with type 2 diabetes or 
the metabolic syndrome also have a high prevalence of subclinical 
vascular inflammation, as determined by high levels of circulating 
inflammatory biomarkers. Indeed, some investigators have 
hypothesized that alterations in innate immunity underlie insulin 
resistance and diabetes
Emerging evidence raises the hypothesis that at least part of the 
anti-inflammatory and atheroprotective effects of low dosis of Mtx 
(LDM) may result from increased adenosine release and subsequent 
agonism of the adenosine A2A receptor. Stimulation of this receptor 
         
Figure 1: Cytoplasmic and nuclear p-65 fractions of NF-κB, VCAM-1 and Il-6 alpha expression in mesenteric arteries detected using WB and IHC. The upper 
panel shows a representative WB probed with anti-VCAM-1-FITC and anti-p65-TRITC. The graphs represent the optical density of the bands for each group. 
The lower panel shows microphotographs of mesenteric tissue obtained using a laser ICM 600x.
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induces the expression of key proteins in reverse cholesterol transport, 
including 27-hydroxylase and adenosine 5’-triphosphate-binding 
cassette transporter A1 (ABCA1), and prevents the formation of foam 
cells from human macrophages. A2A stimulation also attenuates 
inflammation and neointima formation after arterial injury in mice, 
and reduces expression of adhesion molecules commonly associated 
with the development of atheroma, such as vascular cell adhesion 
molecule-1 and intercellular adhesion molecule-1. Direct anti-
inflammatory effects at the level of the vascular endothelium also likely 
have relevance; in New Zealand rabbits consuming a high cholesterol 
diet, weekly intravenous methotrexate administration reduced new 
atheroma formation by 75%, and led to a 2-fold reduction in the 
intima to media ratio and a marked reduction of macrophages and 
apoptotic cells within the aorta intima (Figure 2).
The FFHR experimental model develops hypertension, 
dyslipidaemia, insulin resistance, and vascular and cardiac 
remodelling. Inflammation in this model was demonstrated by 
increased hs-CRP and vascular inflammation due to increased 
expression of NF-kB, VCAM-1 and pro-atherogenic cytokines. The 
increased expression of VCAM-1is a marker of vascular inflammation, 
vascular permeability, and endothelial dysfunction [16-18].
The inflammatory process identified in this experimental model 
has two components: 1- a local component involving an increase in 
the levels of nuclear transcription factors with subsequent activation 
of the inflammatory cascade that results in elevated cytokine levels 
and level 2- a systemic component involving increased hepatic 
synthesis of CRP due to a probable increase in IL-6 levels [10,13,19].
The development of a vascular microenvironment that is conducive 
to the creation, perpetuation, progression, and destabilization of 
vascular injury is either a simple eutrophic mechanism of vascular 
remodelling, or the generation of an atherosclerotic lesion [14,15,20].
A number of mechanisms may underlie these results. IL-6 is a 
well-established, independent indicator of multiple distinct types 
of cardiovascular disease and all-cause mortality. IL-6 is highly 
inducible in vascular tissues through the actions of the angiotensin 
II (Ang II) peptide, where it acts in a paracrine manner to signal 
through two distinct mechanisms; the first is a classic membrane 
receptor-initiated pathway, and the second is a trans-signalling 
pathway that induces responses even in tissues lacking the IL-6 
receptor [21,22]. Recent advances and new concepts on how IL-6 
receptor intracellular signalling pathways operate via the Janus kinase 
(JAK)-Signal Transducer and Activator of Transcription (STAT) 
have been described. IL-6 has diverse actions in multiple cell types 
of cardiovascular importance, including endothelial cells, monocytes, 
platelets, hepatocytes, and adipocytes. The central roles of IL-6 are in 
endothelial dysfunction, cellular inflammation by affecting monocyte 
activation/differentiation, cellular cytoprotective functions from 
reactive oxygen species (ROS) stress, modulation of pro-coagulant 
state, myocardial growth control, and in metabolic control and 
insulin resistance. These multiple actions indicate that IL-6 is not 
merely a passive biomarker, but it actively modulates adaptive and 
pathological responses to cardiovascular stress [23,24].
Our observations elucidated previously unidentified broad 
cardiovascular effects [25] of MTX, which indicate a potential role 
of vascular inflammation modulators that can reduce the vascular 
complications of atherosclerosis-related metabolic syndrome. 
However, further research must be performed to understand if 
the subunit gp130 or inhibition of STAT3 directly produces anti-
inflammatory and anti-angiostensin effects.
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